New maintenance therapy shows promise in preventing relapse after transplant for T-Cell cancers
NCT ID NCT05991973
First seen Jan 05, 2026 · Last updated Apr 25, 2026 · Updated 20 times
Summary
This study tested whether a low dose of the drug chidamide, given after a stem cell transplant, can help prevent T-cell acute lymphoblastic leukemia or T-cell lymphoma from coming back. Forty-four participants received the treatment to see how long they stayed cancer-free and what side effects occurred. The goal was to improve long-term outcomes for people with these aggressive blood cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310006, China
Conditions
Explore the condition pages connected to this study.